Evolution of androgen deprivation therapy

Ganesh V. Raj, Luke A. Selth, Tanya K. Day, Wayne D. Tilley

Research output: Contribution to journalArticle

Abstract

The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/or blocking the androgen receptor, collectively termed androgen deprivation therapy. This review will discuss the evolution of androgen deprivation therapy since it was instigated more than 70 years ago, and outline the key mechanisms underlying its inevitable failure. We will also briefly introduce potential new androgen signalling-targeted therapies in clinical development.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalCancer Forum
Volume39
Issue number3
StatePublished - Nov 1 2015

Fingerprint

Androgens
Therapeutics
Androgen Receptors
Prostatic Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Raj, G. V., Selth, L. A., Day, T. K., & Tilley, W. D. (2015). Evolution of androgen deprivation therapy. Cancer Forum, 39(3), 189-194.

Evolution of androgen deprivation therapy. / Raj, Ganesh V.; Selth, Luke A.; Day, Tanya K.; Tilley, Wayne D.

In: Cancer Forum, Vol. 39, No. 3, 01.11.2015, p. 189-194.

Research output: Contribution to journalArticle

Raj, GV, Selth, LA, Day, TK & Tilley, WD 2015, 'Evolution of androgen deprivation therapy', Cancer Forum, vol. 39, no. 3, pp. 189-194.
Raj GV, Selth LA, Day TK, Tilley WD. Evolution of androgen deprivation therapy. Cancer Forum. 2015 Nov 1;39(3):189-194.
Raj, Ganesh V. ; Selth, Luke A. ; Day, Tanya K. ; Tilley, Wayne D. / Evolution of androgen deprivation therapy. In: Cancer Forum. 2015 ; Vol. 39, No. 3. pp. 189-194.
@article{f48daa22a849418587751ee41ffd0318,
title = "Evolution of androgen deprivation therapy",
abstract = "The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/or blocking the androgen receptor, collectively termed androgen deprivation therapy. This review will discuss the evolution of androgen deprivation therapy since it was instigated more than 70 years ago, and outline the key mechanisms underlying its inevitable failure. We will also briefly introduce potential new androgen signalling-targeted therapies in clinical development.",
author = "Raj, {Ganesh V.} and Selth, {Luke A.} and Day, {Tanya K.} and Tilley, {Wayne D.}",
year = "2015",
month = "11",
day = "1",
language = "English (US)",
volume = "39",
pages = "189--194",
journal = "Cancer Forum",
issn = "0311-306X",
publisher = "The Cancer Council Australia",
number = "3",

}

TY - JOUR

T1 - Evolution of androgen deprivation therapy

AU - Raj, Ganesh V.

AU - Selth, Luke A.

AU - Day, Tanya K.

AU - Tilley, Wayne D.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/or blocking the androgen receptor, collectively termed androgen deprivation therapy. This review will discuss the evolution of androgen deprivation therapy since it was instigated more than 70 years ago, and outline the key mechanisms underlying its inevitable failure. We will also briefly introduce potential new androgen signalling-targeted therapies in clinical development.

AB - The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/or blocking the androgen receptor, collectively termed androgen deprivation therapy. This review will discuss the evolution of androgen deprivation therapy since it was instigated more than 70 years ago, and outline the key mechanisms underlying its inevitable failure. We will also briefly introduce potential new androgen signalling-targeted therapies in clinical development.

UR - http://www.scopus.com/inward/record.url?scp=84963705559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963705559&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84963705559

VL - 39

SP - 189

EP - 194

JO - Cancer Forum

JF - Cancer Forum

SN - 0311-306X

IS - 3

ER -